The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers
نویسندگان
چکیده
منابع مشابه
The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
Women receiving neoadjuvant systemic therapy for primary operable or inoperable breast cancer can potentially benefit in a number of ways, but the main advantage, which has been consistently demonstrated, is improved tumour resectability. Given the improvement in outcomes with the adjuvant use of trastuzumab in patients with early-stage breast cancer positive for the human epidermal growth fact...
متن کاملThe role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
The role of targeted therapies in the treatment of women with breast cancer has been rapidly evolving. Trastuzumab, a monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), was the first HER2-targeted therapy that clearly demonstrated a significant clinical benefit for women with HER2-overexpressing metastatic breast cancer (mbc). However, in recent years it has become...
متن کاملHER2-Targeted Multifunctional Silica Nanoparticles Specifically Enhance the Radiosensitivity of HER2-Overexpressing Breast Cancer Cells
We investigated the effects of targeted functionalized silica nanoparticles on the radiosensitivity of cancer cells. Better control of the local concentration of silica nanoparticles may facilitate their use as an adjuvant in conjunction with ionizing radiation to target cancer cells while preventing damage to normal cells. Hyperbranched polyamidoamine (PAMAM) was grafted onto the surface of am...
متن کاملHER2 Intermediate Breast Cancers.
To the Editor: We were interested to read the article by Gilcrease et al ‘‘Even low level Her2 expression may be associated with worse outcome in node positive breast cancer’’ that discusses the significance of low but nonnegative Her2 protein levels in the prognosis of breast cancer. As the authors note, the conventional immunohistochemical scoring system for Her2 includes cases with 1+ expres...
متن کاملTargeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.
About 20% of all breast cancer patients have a human epidermal growth factor receptor 2 (HER2)-positive breast tumor. This entity underwent an impressive change in prognosis, with notable improvement of progression-free survival and overall survival. Due to more aggressive tumors and no specific therapy, HER2 overexpression was historically seen as a negative prognostic marker, with worse progn...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology
سال: 2009
ISSN: 1718-7729
DOI: 10.3747/co.v16i5.510